Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium.

OBJECTIVE To compare positron emission tomography (PET) and magnetic resonance imaging (MRI) in the evaluation of inflammatory proliferation of synovium. METHODS Ten patients (mean +/- SD age 36 +/- 13 years) with inflammatory joint disease and with clinical signs of inflammation of the joint were studied. A new tracer for cellular proliferation, methyl-(11)C-choline ((11)C-choline), and a widely used tracer for the detection of inflammation and cancer, 2-(18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG), were applied for PET imaging, and the results were compared with the findings from gadolinium diethylenetriaminepentaacetic acid-enhanced MR images. The uptake of (11)C-choline and (18)F-FDG in the inflamed synovium was measured and expressed as the standardized uptake value (SUV) and the kinetic influx constant (K(i)) obtained from graphic analysis, and these values were compared with quantitative values on MRI. Synovial volumes were measured on the coronal contrast-enhanced T1-weighted MR images using the standard software of the MR imager. RESULTS All patients showed high accumulation of both (11)C-choline and (18)F-FDG at the site of arthritic changes, where quantification of the tracer uptake was performed. The SUV of (11)C-choline was 1.5 +/- 0.9 gm/ml (mean +/- SD; n = 10) and the SUV of (18)F-FDG was 1.9 +/- 0.9 gm/ml (n = 10) (P = 0.017). The K(i) of (11)C-choline (mean +/- SD 0.048 +/- 0.042 minute(-1)) was 8-fold higher than the K(i) of (18)F-FDG (0.006 +/- 0.003 minute(-1)) (P = 0.009). Both the uptake of (11)C-choline and the uptake of (18)F-FDG correlated highly with the volume of synovium; the highest correlation was observed with the K(i) of (11)C-choline (r = 0.954, P < 0.0001). CONCLUSION In the use of PET scans,(11)C-choline can be regarded as a promising tracer for quantitative imaging of proliferative arthritis changes. Nevertheless, subsequent prospective studies with larger numbers of patients are necessary to further characterize the relationship between the findings on PET imaging and the clinical and functional measures of inflammation.

[1]  C. Manelfe,et al.  Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. , 1999, Investigative radiology.

[2]  K. Hahn,et al.  The use of [18F]fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses , 2002, Nuclear medicine communications.

[3]  J. Valentin,et al.  Radiation dose to patients from radiopharmaceuticals: (Addendum 2 to ICRP Publication 53) ICRP Publication 80 Approved by the Commission in September 1997 , 1998, Annals of the ICRP.

[4]  J. Pruim,et al.  Carbon-11 choline or FDG-PET for staging of oesophageal cancer? , 2001, European Journal of Nuclear Medicine.

[5]  M. Reiser,et al.  Inflammatory joint disease: Static and dynamic gadolinium‐enhanced MR imaging , 1993, Journal of Magnetic Resonance Imaging.

[6]  H. Minn,et al.  Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography , 2000, European Journal of Nuclear Medicine.

[7]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[8]  Tomio Inoue,et al.  Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging , 2001, European Journal of Nuclear Medicine.

[9]  P. Hannonen,et al.  Value of joint scintigraphy in the prediction of erosiveness in early rheumatoid arthritis. , 1988, Annals of the rheumatic diseases.

[10]  Sven N. Reske,et al.  Experience with carbon-11 choline positron emission tomography in prostate carcinoma , 2000, European Journal of Nuclear Medicine.

[11]  N. Kosaka,et al.  Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. , 1999, Cancer.

[12]  M. Dougados,et al.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. , 1991, Arthritis and rheumatism.

[13]  S. Zeisel.  Dietary choline: biochemistry, physiology, and pharmacology. , 1981, Annual review of nutrition.

[14]  M Ostergaard,et al.  Quantification of synovistis by MRI: correlation between dynamic and static gadolinium-enhanced magnetic resonance imaging and microscopic and macroscopic signs of synovial inflammation. , 1998, Magnetic resonance imaging.

[15]  T Ido,et al.  High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  N. Shinoura,et al.  Brain tumors: detection with C-11 choline PET. , 1997, Radiology.

[17]  A. Fischman,et al.  Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[18]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[19]  W C Eckelman,et al.  Quantitative analysis of tumor biochemisty using PET and SPECT. , 2000, Nuclear medicine and biology.

[20]  H. Minn,et al.  Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS , 2003, Journal of Neuro-Oncology.

[21]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  W E Palmer,et al.  Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1995, Radiology.

[23]  W. Oyen,et al.  Imaging infection/inflammation in the new millennium , 2001, European Journal of Nuclear Medicine.

[24]  J. Pruim,et al.  Visualisation of bladder cancer using 11C-choline PET: first clinical experience , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  Evaluation of alternative approaches for imaging cellular growth. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[27]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[28]  D. J. Valentin.  3. Recalculated dose data for 19 frequently used radiopharmaceuticals from ICRP Publication 53 , 1998 .

[29]  T G Turkington,et al.  Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  M. Bergström,et al.  Positron emission tomography with 11C-D-deprenyl in patients with rheumatoid arthritis. Evaluation of knee joint inflammation before and after intra-articular glucocorticoid treatment. , 1997, Scandinavian journal of rheumatology.

[31]  R. Kauppinen,et al.  Choline‐Containing Compounds in Human Astrocytomas Studied by 1H NMR Spectroscopy In Vivo and In Vitro , 1994, Journal of neurochemistry.

[32]  Abass Alavi,et al.  Positron emission tomography imaging in nonmalignant thoracic disorders. , 2002, Seminars in nuclear medicine.

[33]  F. Mcqueen.  Magnetic resonance imaging in early inflammatory arthritis: what is its role? , 2000, Rheumatology.